Griffiths, C.E.M. and Barker, J.-N.W.N. (2007) Pathogenesis and clinical features of psoriasis. Lancet 370, 263-271
Langley, R.-G.B., Krueger, G.G. and Griffiths, C.E.M. (2005) Psoriasis: epidemiology, clinical features, and quality of life. Ann. Rheum. Dis. 64, ii18-ii23
Feldman, S.R., Zhao, Y., Navaratnam, P., Friedman, H.S., Lu, J. and Tran, M.H. (2015) Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis. J. Manag. Care Spec. Pharm. 21, 201-209
Brezinski, E.A. and Armstrong, A.W. (2012) Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy. PLoS ONE 7, e33486
Radstake, T.R., Svenson, M., Eijsbouts, A.M., van den Hoogen, F.H., Enevold, C., van Riel, P.L. et al. (2009) Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann. Rheum. Dis. 68, 1739-1745
Moss, A., Brinks, V. and Carpenter, J.F. (2013) Review article: immunogenicity of anti-TNF biologics in IBD -the role of patient, product and prescriber factors. Aliment. Pharmacol. Ther. 38, 1188-1197
Dauden, E., Griffiths, C., Ortonne, J.P., Kragballe, K., Molta, C., Robertson, D. et al. (2009) Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. J. Eur. Acad. Dermatol. Venereol. 23, 1374-1382
Strohal, R., Chimenti, S., Vena, G.A. and Girolomoni, G. (2013) Etanercept provides an effective, safe and flexible short-and long-term treatment regimen for moderate-to-severe psoriasis: a systematic review of current evidence. J. Dermatolog. Treat. 24, 199-208
Segaert, S., Ghislain, P.-D. and Boone, C. (2016) An observational study of the real-life management of psoriasis patients treated with etanercept according to the new reimbursement criteria (in Belgium). J. Dermatolog. Treat. 27, 103-109
Detrez, I., Brouwers, E., Peeters, M., Geukens, N., de Vlam, K. and Gils, A. (2016) Characterization and application of a unique panel of monoclonal antibodies generated against etanercept. J. Immunol. 196, 2879-2884
Bourdage, J.S., Cook, C.A., Farrington, D.L., Chain, J.S. and Konrad, R.J. (2007) An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug. J. Immunol. Methods 327, 10-17
Verbeke, G. and Molenberghs, G. (1997) Linear Mixed Models in Practice: A SAS-Oriented Approach, Springer-Verlag, New York
Sterry, W., Ortonne, J.-P., Kirkham, B., Brocq, O., Robertson, D., Pedersen, R.D. et al. (2010) Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 340, c147
Ben-Horin, S., Chowers, Y., Ungar, B., Kopylov, U., Loebstein, R., Weiss, B. et al. (2015) Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal. Aliment. Pharmacol. Ther. 42, 356-364
Papamichael, K., Casteele, N.V., Gils, A., Tops, S., Hauenstein, S., Singh, S. et al. (2015) Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remission. Clin. Gastroenterol. Hepatol. 13, 1103-1110
Elberdin , L., Outeda, M., Salvador, P., Paradela, S., Ferná ndez-Torres, R.M., Iglesias, R. et al. (2016) Positive correlation between etanercept concentration and the decrease in Psoriasis Area and Severity Index scale value. Int. J. Clin. Pharm. 38, 1142-1148
Kneepkens, E., Krieckaert, C., van der Kleij, D., Nurmohamed, M., van der Horst-Bruinsma, I., Rispens, T. et al. (2015) Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up. Ann. Rheum. Dis. 74, 1825-1829
Hasegawa, Y., Sawada, M., Ozaki, N., Inagaki, T. and Suzumura, A. (2000) Increased soluble tumor necrosis factor receptor levels in the serum of elderly people. Gerontology 46, 185-188
de Vries, M.K., van der Horst-Bruinsma, I.E., Nurmohamed, M.T., Aarden, L.A., Stapel, S.O., Peters, M.J. et al. (2009) Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann. Rheum. Dis. 68, 531-535
Jullien, D., Prinz, J.C. and Nestle, F.O. (2015) Immunogenicity of biotherapy used in psoriasis: the science behind the scenes. J. Invest. Dermatol. 135, 31-38
Detrez, I., Dreesen, E., Van Stappen, T., de Vries, A., Brouwers, E., Van Assche, G. et al. (2016) Variability in golimumab exposure: a 'real-life' observational study in active ulcerative colitis. J. Crohns Colitis 10, 575-581
Casteele, N.V., Gils, A., Singh, S., Ohrmund, L., Hauenstein, S., Rutgeerts, P. et al. (2013) Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am. J. Gastroenterol. 108, 962-971
Clark, L. and Lebwohl, M. (2008) The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J. Am. Acad. Dermatol. 58, 443-446
